The latest biologic for psoriasis – bimekizumab – provides more rapid and complete clearance of symptoms than current mAbs through a novel dual action inhibiting IL-17A and IL-17F, two studies suggest. The drug has the potential to become the drug of choice for more resistant psoriasis, although there are still questions about its adverse effects ...
Dual IL-17A and IL-17F inhibitor provides complete skin clearance in psoriasis
By Michael Woodhead
10 Feb 2021